Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to initiate a Phase 3 Clinical Trial of intralesional rhEGF for the treatment of diabetic foot ulcers
April 30, 2024 09:00 ET
|
Discovery Therapeutics Caribe, LLC
FDA approves Discovery Therapeutic Caribe's Phase 3 trial for intralesional rhEGF in severe diabetic foot ulcers.
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Global Drug Infusion System Market Size Grows Steadily at a CAGR of 6.9%: Straits Research
April 29, 2024 10:05 ET
|
Straits Research Private Limited - Reed Intelligence
New York, United States, April 29, 2024 (GLOBE NEWSWIRE) -- A drug infusion system is a medical device that allows fluids, medicines, and therapeutic substances to be administered directly into a...
Intuity Medical is Providing Insured People with Diabetes Easier Access to POGO Automatic Through HealthHavenRx™ eCommerce Partnership
April 11, 2024 09:00 ET
|
Intuity Medical
FREMONT, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Intuity Medical, Inc., the medical technology company committed to making it easier to live with diabetes, is announcing a partnership with...
LiveCare Inc. (OTCMKTS: LVCE) Marks Monumental Revenue Milestone Setting Eyes on Profitability
April 11, 2024 09:00 ET
|
LiveCare Inc.
Venice, FL, April 11, 2024 (GLOBE NEWSWIRE) -- LiveCare Inc. (OTCMKTS: LVCE), a pioneering force in the telehealth sector, proudly announces a significant financial milestone, having surpassed...
UMeWorld to Debut the World's First & Only Weight Loss Cooking Oil in the US
April 09, 2024 08:00 ET
|
UMeWorld Limited
MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is excited to announce that the company has secured an exclusive license to use proprietary enzymatic technologies to...
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
April 04, 2024 07:57 ET
|
ZyVersa Therapeutics
Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
April 02, 2024 10:59 ET
|
Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today unveiled an...
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Global Insulin Glargine Market Size is projected to reach USD 2200 million by 2031, growing at a CAGR of 6.11%: Straits Research
March 20, 2024 10:50 ET
|
Straits Research Private Limited - Reed Intelligence
New York, United States, March 20, 2024 (GLOBE NEWSWIRE) -- Insulin glargine is a modified, long-acting form of medical insulin used to treat diabetes types I and II. It is subcutaneously injected....